What it is
Survodutide is a dual agonist of the GLP-1 and glucagon receptors.
Unpacking that: GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases when you eat, which suppresses appetite. Glucagon is a separate hormone, made by the pancreas, that raises blood sugar and increases the rate at which the body burns energy. An agonist is something that copies a hormone and switches on the same receptors. "Dual" means Survodutide acts on both sets of receptors at once.
It was originally developed as a treatment for Type-2 diabetes and obesity. Like other GLP-1 drugs, it suppresses appetite, increases fat oxidation — the burning of fat for fuel — and supports metabolic activity.
It has also shown promise as a treatment for two liver conditions: non-cirrhotic MASH, which stands for metabolic-dysfunction-associated steatohepatitis and means a fatty, inflamed liver not yet scarred into cirrhosis; and moderate liver fibrosis at the F2 to F3 stage, meaning scarring of the liver that has progressed but not to the final stage.
It arrives as a dry powder in a sealed vial. You add bacteriostatic water — sterile water with a preservative, so it keeps for weeks — then inject just under the skin, a subcutaneous injection, once a week.
One notable point: in clinical trials Survodutide showed milder side effects than other GLP-1 drugs.
Survodutide is a dual GLP-1 / glucagon receptor agonist, developed originally for Type-2 diabetes and obesity.
The glucagon receptor arm is the point of difference from the GLP-1 / GIP dual agonists: rather than adding a second incretin, it adds an energy-expenditure and hepatic-lipid lever, which is what underlies the MASH signal.
Stated actions: appetite suppression, increased fat oxidation, and support for metabolic activity, in common with the GLP-1 class.
Hepatic indication: promise in non-cirrhotic metabolic-dysfunction-associated steatohepatitis (MASH) and moderate liver fibrosis at F2–F3.
Trial outcomes cited: 6 inches average waist circumference reduction at 46 weeks; 19% total body weight loss at 4.8 mg weekly; significant blood pressure reduction at 2.4 mg and above; ongoing weight loss continuing past 46 weeks, suggesting greater fat reduction with longer use.
Tolerability: milder side-effect profile than other GLP-1 drugs in trials — the reported list is short, running to injection site irritation, nausea, vomiting, and diarrhoea only.
Subcutaneous, once weekly, reconstituted in bacteriostatic water, titrated in 0.8 mg increments.
What it does
Weight and waist: at 46 weeks, participants lost an average of 6 inches from their waist circumference. At 4.8 mg weekly, total body weight loss reached 19%. Weight loss was still continuing past 46 weeks, a sign that longer use may produce greater fat reduction.
Appetite and metabolism: like other GLP-1 drugs, it suppresses appetite, increases fat oxidation — the burning of fat for fuel — and supports metabolic activity.
Blood pressure: there was a significant reduction in blood pressure at doses of 2.4 mg or higher.
Heart: it is described as potentially beneficial for cardiovascular health.
Liver: it has shown promise as a treatment for a fatty, inflamed liver that has not yet scarred into cirrhosis, and for moderate liver scarring.
Anthropometric: 6 inches average waist circumference reduction at 46 weeks; 19% total body weight loss at 4.8 mg weekly; loss still ongoing past 46 weeks, suggesting further fat reduction with extended use.
Metabolic: appetite suppression, increased fat oxidation, support for metabolic activity — the glucagon arm contributes energy expenditure that a pure incretin agonist does not.
Haemodynamic: significant blood pressure reduction at doses ≥ 2.4 mg. Note the interaction consequence — combining with antihypertensives carries an explicit warning.
Cardiovascular: described as potentially beneficial.
Hepatic: promise in non-cirrhotic MASH and moderate (F2–F3) fibrosis.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- At 46 weeks, participants lost an average of 6 inches from waist circumference.Human trials
- 19% total body weight loss at 4.8 mg weekly.Human trials
- Significant reduction in blood pressure at 2.4 mg or higher.Human trials
- Potentially beneficial for cardiovascular health.Limited human data
- Weight loss continued past 46 weeks, suggesting longer-term use may produce greater fat reduction.Human trials
- Suppresses appetite.Limited human data
- Increases fat oxidation — the burning of fat for fuel.Animal or lab only
- Supports metabolic activity.Animal or lab only
- Has shown promise for a fatty, inflamed liver that has not yet scarred into cirrhosis, and for moderate liver scarring.Human trials
- Milder side effects than other GLP-1 drugs in clinical trials.Anecdotal
- 6 inches average waist circumference reduction at 46 weeks.Human trials
- 19% total body weight loss at the 4.8 mg weekly dose.Human trials
- Significant blood pressure reduction at ≥ 2.4 mg.Human trials
- Potentially beneficial for cardiovascular health.Limited human data
- Weight loss ongoing beyond 46 weeks, implying greater fat reduction with extended use.Human trials
- Appetite suppression, increased fat oxidation, and metabolic support.Animal or lab only
- Promise in non-cirrhotic MASH and F2–F3 liver fibrosis.Human trials
- Milder trial side-effect profile than other GLP-1 agents.Anecdotal
Reconstitution and dosing
One vial size is covered: 10 mg, mixed with 1.5 mL (150 units) of bacteriostatic water. "Units" means the marks on an insulin syringe — 100 units is 1 mL.
Inject under the skin, once a week, always on the same day each week.
Begin at 1.6 mg — 24 units — and stay at that dose for at least four weeks before considering an increase. Doses go up in 0.8 mg steps: 0.8, 1.6, 2.4, 3.2, 4, 4.8, 5.6, and 6.4 mg, which is the maximum.
The 4.8 mg step is the dose that produced 19% weight loss in the clinical trial.
Stay on each dose for at least four weeks before increasing.
Note that 0.8 mg appears in the chart but is below the recommended starting point of 1.6 mg.
Single presentation: 10 mg in 1.5 mL (150 units) of bacteriostatic water, giving 6.67 mg/mL. Unit draws have been checked against the dose in milligrams at every step.
Subcutaneous, once weekly, fixed day. Minimum four weeks at each dose before escalation.
Starting dose is 1.6 mg (24 units), not the lowest rung on the chart — 0.8 mg (12 units) is listed, but users should begin at 1.6 mg.
Escalation is in 0.8 mg increments: 0.8, 1.6, 2.4, 3.2, 4.0, 4.8, 5.6, 6.4 mg. 4.8 mg is the trial dose associated with 19% weight loss; 6.4 mg is the stated maximum.
Two dose-dependent thresholds worth tracking: blood pressure reduction becomes significant at ≥ 2.4 mg, which is where the antihypertensive interaction warning bites.
10 mg vial
Mix with 1.5 mL (150 units) of bacteriostatic water.
6.67 mg/mL · 66.67 mcg per unit
Frequency: Once weekly, subcutaneous, always the same day each week; stay on each dose at least 4 weeks before increasing; doses rise in 0.8 mg increments
| When | Dose | Draw | How often |
|---|---|---|---|
| 0.8 mg (below the recommended starting dose) | 800 mcg | 12 units | once weekly |
| 1.6 mg — recommended starting dose; hold at least 4 weeks | 1.6 mg | 24 units | once weekly |
| 2.4 mg | 2.4 mg | 36 units | once weekly |
| 3.2 mg | 3.2 mg | 48 units | once weekly |
| 4 mg | 4 mg | 60 units | once weekly |
| 4.8 mg — clinical trial dose for 19% weight loss | 4.8 mg | 72 units | once weekly |
| 5.6 mg | 5.6 mg | 84 units | once weekly |
| 6.4 mg — maximum dose | 6.4 mg | 96 units | once weekly |
10 mg in 1.5 mL is 6.67 mg/mL, or 66.67 mcg per unit. Draw 12 units (0.12 mL) for 800 mcg.
Who should avoid it
- Anyone pregnant or breastfeeding.
- If you are on blood pressure medication, you need monitoring — Survodutide may interact with it. Survodutide also lowers blood pressure at 2.4 mg and above, so it is worth watching for the two effects adding together; whether they do has not been established.
- Do not stop all your blood pressure medication without consulting a doctor. This may offset the benefits Survodutide provides.
- Talk to a doctor before starting.
- Pregnancy or breastfeeding.
- Patients on antihypertensive medication require monitoring — Survodutide's own blood pressure reduction at ≥ 2.4 mg is additive with antihypertensive therapy.
- Do not discontinue all antihypertensive therapy without physician consultation; this may offset Survodutide's benefits.
- These three points are the known contraindications.
Side effects
- Survodutide showed milder side effects than other GLP-1 drugs in clinical trials.
- Injection site irritation — redness, swelling, itching.
- Nausea.
- Vomiting.
- Diarrhoea.
- Milder profile than the rest of the GLP-1 class in trials.
- Injection site irritation (erythema, swelling, pruritus).
- Nausea.
- Vomiting.
- Diarrhoea.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
Alternate between cycles rather than combining, to stop the GLP-1 receptors becoming desensitised — that is, less responsive over time.
Alternate between cycles rather than co-administer; the stated rationale is prevention of GLP-1 receptor desensitisation. Note the GLP2-T page independently grades other GLP peptides as a severe interaction on receptor redundancy, which supports rotation over combination.
Listed alongside GLP2-T as a compound to alternate with between cycles, not to combine with.
Same rotation logic — cycle-level alternation to preserve GLP-1 receptor sensitivity.
Enhances cellular energy production and repair of the mitochondria — the parts of your cells that generate energy — alongside fat loss.
Cellular energy production and mitochondrial repair during the deficit. Survodutide + Glutathione + NAD+ is a common triad for metabolic and liver optimisation.
The other option in the same slot as NAD+ for cellular energy and mitochondrial repair.
Mitochondrial-derived peptide, grouped with NAD+ for energy production and mitochondrial repair alongside fat loss.
Further supports fat breakdown during the phase when Survodutide is suppressing appetite.
Adds direct lipolysis to the appetite-driven deficit. AOD-9604 plus CJC-1295/Ipamorelin is a common fat-loss stack for preserving lean mass and speeding recovery.
- L-Carnitine injections
Promotes the transport of fat into the mitochondria so it can be burned.
Fatty acid transport into mitochondria for oxidation — pairs with the fat-oxidation increase Survodutide already produces.
- Glutathione
Reduces oxidative stress — damage to cells from unstable molecules — and supports liver function. This matters especially for people with fatty liver disease.
Oxidative stress reduction and hepatic support, called out specifically for MASH patients. Part of the Survodutide + Glutathione + NAD+ triad for metabolic and liver optimisation.
Enhances lean muscle gain during weight loss phases.
Lean mass support through the deficit; the fat-loss stack pairs it with AOD-9604 to preserve lean tissue and speed recovery.
Dosing figures have been reviewed and units are recomputed from the stated protocol.